About US


Founded in April 2019, JunRui Biotechnology focuses on the discovery, development and commercialization of antineoplastic drugs through collaboration with both academy and industry. In particular, Junrui Biotechnology has developed a series of novel small molecule anti-cancer agents based on CXCR4/CXCL12 signal axis.

In the future, under the leadership of co-founders, JunRui Biotechnology will continue to research and develop first-in-class or best-in-class anti-cancer drugs, enriching the company's R&D pipeline and exploring novel therapies in oncology and related fields, to meet the unmet medical need for patients in China and around the globe.

Delivering drugs with better effectiveness, higher quality and lower cost